Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP5 | P24593 | 4/20 | 0.43 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 5/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ESRRB | O95718 | 3/20 | 0.41 |
| ▸ | ESRRA | P11474 | 3/20 | 0.41 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905794 | 0.87 | IGFBP5 (0.46) | IGFBP5IGFBP3ESR1ESR2ALOX15 | |
| SCHEMBL11827386 | 0.84 | IGFBP5 (0.47) | IGFBP5IGFBP3ALOX15TSHRALDH1A1 | |
| SCHEMBL31553431 | 0.84 | ESR1 (0.49) | IGFBP5ESR1ESR2ALOX15CA12 | |
| SCHEMBL2908985 | 0.84 | ALOX15 (0.48) | IGFBP5IGFBP3ESR2ALOX15CA12 | |
| SCHEMBL27816391 | 0.83 | ALOX15 (0.44) | IGFBP3ALOX15ALDH1A1MGAM | |
| SCHEMBL11823904 | 0.82 | IGFBP5 (0.46) | IGFBP5IGFBP3ALOX15TSHRALDH1A1 | |
| SCHEMBL2907367 | 0.82 | IGFBP3 (0.48) | IGFBP5IGFBP3ESR2ALOX15TSHR | |
| SCHEMBL2908145 | 0.82 | DHODH (0.48) | IGFBP5IGFBP3ALDH1A1 | |
| SCHEMBL9039085 | 0.82 | ALDH1A1 (0.48) | ESR1ESR2ALOX15ALDH1A1 | |
| SCHEMBL1305232 | 0.82 | ALDH1A1 (0.49) | IGFBP5IGFBP3CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285544-A | Method for separating and preparing natural 6-hydroxykynurenic acid from ginkgo leaves | 浙江理工大学绍兴生物医药研究院有限公司 | 2025-01-10 | — | — | CN | claimed |
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS INC. | 2024-09-03 | — | — | US | claimed |
| WO-2023246355-A1 | GINKGO LEAF ORGANIC ACID EXTRACT, METHOD FOR PREARING SAME AND USE THEREOF | 浙江康恩贝制药股份有限公司 | 2023-12-28 | — | — | WO | claimed |
| CN-115006435-B | Ginkgo leaf organic acid extract and preparation method and application thereof | 浙江康恩贝制药股份有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-115894515-A | Method for integrated extraction, enrichment, separation and purification of effective components of ginkgo leaves in full industrial chain | 李玉山 | 2023-04-04 | — | — | CN | claimed |
| CN-114366761-B | Preparation method of ginkgo leaf extract rich in organic acid | 江苏得乐康生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115006435-A | Ginkgo leaf organic acid extract and preparation method and application thereof | 浙江康恩贝制药股份有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-114366761-A | Preparation method of ginkgo leaf extract rich in organic acid | 江苏得乐康生物科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-31 | — | — | US | claimed |
| US-11234975-B2 | Levorphanol prodrugs and processes for making and using them | KEMPHARM, INC. (US) | 2022-02-01 | — | — | US | claimed |
| WO-2016086113-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE | KEMPHARM, INC. (US) | 2016-06-02 | — | — | WO | claimed |
| CN-104136031-A | Benzoic acid, benzoic acid derivative and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and using thereof | KEMPHARM INC | 2014-11-05 | — | — | CN | claimed |
| EP-2771002-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| EP-2736510-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2014-06-04 | — | — | EP | claimed |
| CN-103826633-A | Methylphenidate prodrugs, methods of making and using the same | KEMPHARM INC | 2014-05-28 | — | — | CN | claimed |
| US-20130150395-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2013-06-13 | — | — | US | claimed |
| WO-2013063204-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2013016668-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC. (US) | 2013-01-31 | — | — | WO | claimed |
| CN-102133243-A | Folium ginkgo extract containing 6-hydroxykynurenic acid | SHANGHAI NOVANAT BIORESOURCES CO LTD | 2011-07-27 | — | — | CN | claimed |
| CN-1965870-A | Pharmaceutical composition containing ligustrazine and effective component of ginkgo leaf and formulation thereof | BEIJING TIANXINYUAN MEDICINE T (CN) | 2007-05-23 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | IGFBP5 2181/4885IGFBP3 829/4885ESR1 3275/4885 |
| US-11234975-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | IGFBP5 2181/4885IGFBP3 829/4885ESR1 3275/4885 |
| US-20130150395-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, CYP2D6 | IGFBP5 3980/4885IGFBP3 4501/4885ESR1 561/4885 |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | IGFBP5 2181/4885IGFBP3 829/4885ESR1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.